Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Total Liabilities (2021 - 2025)

Coeptis Therapeutics Holdings has reported Total Liabilities over the past 5 years, most recently at $2.1 million for Q4 2025.

  • Quarterly results put Total Liabilities at $2.1 million for Q4 2025, down 58.63% from a year ago — trailing twelve months through Dec 2025 was $2.1 million (down 58.63% YoY), and the annual figure for FY2025 was $2.1 million, down 58.63%.
  • Total Liabilities for Q4 2025 was $2.1 million at Coeptis Therapeutics Holdings, down from $3.3 million in the prior quarter.
  • Over the last five years, Total Liabilities for COEPW hit a ceiling of $10.4 million in Q2 2021 and a floor of $2.1 million in Q4 2025.
  • Median Total Liabilities over the past 5 years was $4.6 million (2022), compared with a mean of $4.9 million.
  • Biggest five-year swings in Total Liabilities: plummeted 60.64% in 2022 and later soared 43.04% in 2024.
  • Coeptis Therapeutics Holdings' Total Liabilities stood at $4.4 million in 2021, then fell by 21.58% to $3.5 million in 2022, then grew by 8.51% to $3.8 million in 2023, then surged by 34.18% to $5.0 million in 2024, then tumbled by 58.63% to $2.1 million in 2025.
  • The last three reported values for Total Liabilities were $2.1 million (Q4 2025), $3.3 million (Q3 2025), and $5.1 million (Q2 2025) per Business Quant data.